Trown P W, Kramer M J, Dennin R A, Connell E V, Palleroni A V, Quesada J, Gutterman J U
Lancet. 1983 Jan 15;1(8316):81-4. doi: 10.1016/s0140-6736(83)91737-3.
During the course of clinical investigation of partly purified human leucocyte interferon (IFN) prepared at the Finnish Red Cross (PIF), neutralising IgG antibodies to human leucocyte IFN were detected in the sera of 3 patients with cancer. In 2 of these patients, the antibodies were detected in serum before treatment with PIF. In the third patient antibodies developed during the course of treatment. Antibody titres against six recombinant human leucocyte IFN sub-types and one recombinant hybrid human leucocyte IFN were different in the 3 patients.
在对芬兰红十字会制备的部分纯化人白细胞干扰素(PIF)进行临床研究的过程中,在3例癌症患者的血清中检测到了针对人白细胞干扰素的中和性IgG抗体。在其中2例患者中,在使用PIF治疗前血清中就检测到了抗体。在第3例患者中,抗体在治疗过程中产生。这3例患者针对6种重组人白细胞干扰素亚型和1种重组杂交人白细胞干扰素的抗体滴度各不相同。